Teva's first quarter 2026 revenue of $4.0B beats estimates, driven by 41% AUSTEDO growth.

Teva reported first quarter revenue of approximately $4.0 billion and non-GAAP EPS of $0.53, slightly beating analyst expectations. The results were driven by strong growth in the innovative brand portfolio, which offset expected declines in the generics business due to increased competition for the generic version of Revlimid.

Key Highlights

• AUSTEDO global revenue grew 41% year-over-year to $578 million, significantly outpacing expectations and driving the company's performance.
• The broader innovative portfolio also showed strong momentum, with AJOVY global revenue up 35% to $196 million and UZEDY revenue up 62% to $63 million.
• U.S. generic product revenue declined 28% to $612 million, primarily due to increased competition for lenalidomide (generic Revlimid), highlighting the importance of the company's pivot to innovative drugs.
• Teva announced a definitive agreement to acquire Emalex Biosciences, a move intended to accelerate its 'Pivot to Growth' strategy by strengthening its neuroscience pipeline.